Back to Browse Journals » Vascular Health and Risk Management » Volume 9

Atrial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherence

Authors Ferguson C, Inglis SC, Newton PJ, Middleton S, Macdonald PS, Davidson PM

Published Date January 2013 Volume 2013:9 Pages 3—11

DOI http://dx.doi.org/10.2147/VHRM.S39571

Received 25 October 2012, Accepted 10 December 2012, Published 17 January 2013

Caleb Ferguson,1 Sally C Inglis,1 Phillip J Newton,1 Sandy Middleton,2,3 Peter S Macdonald,3,4 Patricia M Davidson1,3

1Center for Cardiovascular and Chronic Care, University of Technology, 2National Center for Clinical Outcomes Research (NaCCOR), Australian Catholic University, 3St Vincent's Hospital, Darlinghurst, Sydney, Australia; 4Victor Chang Cardiac Research Institute, University of New South Wales, Sydney, Australia

Abstract: Atrial fibrillation is a common arrhythmia in heart failure and a risk factor for stroke. Risk assessment tools can assist clinicians with decision making in the allocation of thromboprophylaxis. This review provides an overview of current validated risk assessment tools for atrial fibrillation and emphasizes the importance of tailoring individual risk and the importance of weighing the benefits of treatment. Further, this review provides details of innovative and patient-centered methods for ensuring optimal adherence to prescribed therapy. Prior to initiating oral anticoagulant therapy, a comprehensive risk assessment should include evaluation of associated cardiogeriatric conditions, potential for adherence to prescribed therapy, frailty, and functional and cognitive ability.

Keywords: stroke risk, heart failure, atrial fibrillation, anticoagulation, risk stratification, medication adherence

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Assessment of ZnO and SiO2 nanoparticle permeability through and toxicity to the blood–brain barrier using Evans blue and TEM

Shim KH, Jeong KH, Bae SO, Kang MO, Maeng EH, Choi CS, Kim YR, Hulme J, Lee EK, Kim MK, An SSA

International Journal of Nanomedicine 2014, 9:225-233

Published Date: 15 December 2014

Effects of exercise timing on sleep architecture and nocturnal blood pressure in prehypertensives

Fairbrother K, Cartner B, Alley JR, Curry CD, Dickinson DL, Morris DM, Collier SR

Vascular Health and Risk Management 2014, 10:691-698

Published Date: 12 December 2014

Preparation of bufalin-loaded pluronic polyetherimide nanoparticles, cellular uptake, distribution, and effect on colorectal cancer

Hu Q, Liang B, Sun Y, Guo XL, Bao YJ, Xie DH, Zhou M, Duan YR, Yin PH, Peng ZH

International Journal of Nanomedicine 2014, 9:4035-4041

Published Date: 21 August 2014

Epidemiology of stroke in a rural community in Southeastern Nigeria

Enwereji KO, Nwosu MC, Ogunniyi A, Nwani PO, Asomugha AL, Enwereji EE

Vascular Health and Risk Management 2014, 10:375-388

Published Date: 24 June 2014

MRI-based identification of undifferentiated cells: looking at the two faces of Janus

Tomuleasa C, Florian IS, Berce C, Irimie A, Berindan-Neagoe I, Cucuianu A

International Journal of Nanomedicine 2014, 9:865-866

Published Date: 11 February 2014

Efficacy of reduced-fluence photodynamic therapy for serous retinal pigment epithelial detachment with choroidal hyperpermeability

Shibata A, Ohkuma Y, Hayashi T, Tsuneoka H

Clinical Ophthalmology 2013, 7:2123-2126

Published Date: 30 October 2013

Reduced prefrontal cortex activation using the Trail Making Test in schizophrenia

Fujiki R, Morita K, Sato M, Kamada Y, Kato Y, Inoue M, Shoji Y, Uchimura N

Neuropsychiatric Disease and Treatment 2013, 9:675-685

Published Date: 16 May 2013

An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma

Shen M, Gong FM, Pang PF, Zhu KS, Meng XC, Wu C, Wang J, Shan H, Shuai XT

International Journal of Nanomedicine 2012, 7:3319-3332

Published Date: 2 July 2012